ArticleBrain & spine2026
Does pattern of 5-aminolevulinic acid (5-ALA) residual intra-operatively predict worse outcome in glioblastoma?
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and research question: 5-Aminolevulinic acid (5-ALA) guidance helps to maximize surgical resection in Glioblastoma (GBM). It is unclear if the residual 5-ALA pattern can predict the outcome of GBM patients. Material and methods: Patients with GBM treated at our center between January 2018 - Jun 2022 were included. The pattern of 5-ALA residual was classified as Results: Total of 120 patients were screened and 46 were included. The majority of patients presented with temporal lesion (50%) and gross total resection was achieved in 56.52%. No 5-ALA residual was seen in 50% of patients; 39% had focal and 11% had diffuse residual. The pattern of 5-ALA residual - none or focal Conclusion: Diffuse 5-ALA residual is a poor prognostic factor for OS and PFS. The absence of a survival benefit of none over focal 5-ALA residual at the end of resection is important for intraoperative decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.